News

ProMIS Neurosciences hopes to develop an ALS therapy around a component of a protein that is faulty in the disease. The TDP43 protein’s abnormality leads to it becoming misfolded — that is, it not having a normal structure — in both amyotrophic lateral sclerosis and frontotemporal dementia (FTD). ProMIS thinks it can eliminate…

Researchers have identified the sequence of molecular events leading to motor neuron death in amyotrophic lateral sclerosis (ALS), an important step forward that may lead to new therapies to halt this process. They found that unlike healthy astrocytes, which are…

Radicava, also known by its generic name edaravone, is the first treatment approved by U.S. Food and Drug Administration (FDA) in more than two decades to help amyotrophic lateral sclerosis (ALS) patients. While awaiting its arrival, ALS News Today spoke to the company responsible for its U.S. launch,…

Mindfulness-based programs may help improve anxiety and depression in patients with amyotrophic lateral sclerosis (ALS), according to results of a study published recently in the European Journal of Neurology. The study is titled “Meditation training for people with amyotrophic lateral sclerosis: a randomized clinical trial.” The journal also published…

An artificial-intelligence-proposed ALS therapy prevented the death of movement-control neurons in a lab and delayed the onset of the disease in an animal model, according to British scientists. The University of Sheffield team said the AI company BenevolentAI suggested the therapy, which has yet to have a name. The drug candidate promotes…

An imbalance between production and degradation of protein in the central nervous system may contribute to amyotrophic lateral sclerosis (ALS), researchers at England’s University of Sheffield suggest. Their study, “Protein Homeostasis in Amyotrophic Lateral Sclerosis: Therapeutic Opportunities?,” appeared in the journal Frontiers in Molecular Neuroscience. It reviewed available data showing that disturbances in…

HVH Precision Analytics presented findings of its big data analysis for earlier diagnosis of ALS (amyotrophic lateral sclerosis) to help clinicians treat patients sooner and allow patients to possibly enroll in clinical trials. HVH’s poster presentation, titled “Big Data Analytics for Early Diagnosis of Amyotrophic Lateral Sclerosis (ALS),” took place at…

Researchers at Ben-Gurion University (BGU) believe that an existing FDA-approved anti-cancer drug, rituximab, could be modified and used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. In lab studies with mice, the therapy restored resident immune cells of the central nervous system, which could indicate…

Data from the open-label extension trial of Radicava (edaravone) in patients with amyotrophic lateral sclerosis (ALS) demonstrated that the treatment continued to provide benefits after 48 weeks of treatment. These findings — presented by researchers from MT Pharma America at the May 18-20 European Network for the Cure…

French biotech company AB Science presented the results of the Phase 3 clinical trial for its lead compound masitinib, which showed effectiveness in improving the functioning of patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The randomized, double-blind clinical trial (NCT02588677) compared the efficacy and…